HMGCR

There are 177 papers on HMGCR in aging research: 20 trials and 38 observational studies in people, 49 in animals, 20 in cells, 41 reviews.

Gene

177 papers study it27 findings

HGNCNCBI GeneTaxon

11 new papers in 30 daysSee all 177 papers on HMGCR

At a glance

The findings reach people, from one lab or study. 17 independent labs in 8 countries; 238 trials, 153 with no results posted.

“The lipid-lowering variants of HMGCR, PCKS9, LPL, and APOB were associated with longer lifespans but did not causally increase extreme longevity.”
Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysisLipids in health and disease2023doi:10.1186/s12944-023-01983-0

2 of its findings point the other way.

Cells, worms or flies, mice and humans: a single group.
  • 17 independent labs in 8 countries
  • 2 findings against
  • 238 trials, 153 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 2 of 23 findings with company ties
  • 148 of 238 trials sponsored by developers of drugs aimed at it
  • Human trial20
  • Humans38
  • Animals44
  • Model organisms5
  • Cells20
  • In silico1

Interventions

4

Caloric restriction

upin rats1downin rats1

2 studies
  1. Caloric restriction increases HMGCR in aging rats.

    Animalsin aging rats

  2. Caloric restriction decreases HMGCR in rats during ageing.

    Animalsduring ageingliver

More on Caloric restriction

Flavonoids and their metabolites

downin reviews1

1 study
  1. Flavonoids and their metabolites inhibit HMGCR (management of hyperlipidaemia).

    Reviewmanagement of hyperlipidaemia

More on Flavonoids and their metabolites

Resveratrol

downin mice1

1 study
  1. Resveratrol decreases HMGCR in SAMP8 mice.

    Animalsin SAMP8 micecerebellum

More on Resveratrol

Vitamin E

upin rats1

1 study
  1. Vitamin E increases HMGCR in rats.

    Animalsliver

More on Vitamin E

Effects

6

Appendicular lean mass

no changein humans1upin humans1

2 studies
  1. HMGCR was not clearly linked with appendicular lean mass in humans (genetically proxied inhibition, two-sample Mendelian randomization) (beta 0.048 (95% CI -0.015 to 0.110), P = 0.14).

    Humansgenetically proxied inhibition, two-sample Mendelian randomization

  2. HMGCR is linked with higher appendicular lean mass in humans (genetically proxied inhibition, Mendelian randomization using UK Biobank LDL-C data) (beta = 0.087, P = 7.56 × 10-5).

    Humansgenetically proxied inhibition, Mendelian randomization using UK Biobank LDL-C data

Osteoarthritis

downin mice1

1 study
  1. HMGCR decreases osteoarthritis in OA mice via intra-articular AAV delivery.

    Animalsin OA mice via intra-articular AAV deliverysynovium

More on Osteoarthritis

Cognitive function

downin silico1

1 study
  1. HMGCR impairs cognitive function in Parkinson's disease.

    In silicoin Parkinson's disease

Lifespan

upin flies1

1 study
  1. HMGCR extends lifespan in flies (cardiac Hmgcr upregulation).

    Model organismscardiac Hmgcr upregulationheart

Cardiac function

upin flies1

1 study
  1. HMGCR improves cardiac function in flies (cardiac Hmgcr upregulation).

    Model organismscardiac Hmgcr upregulationheart

Walking pace

downin humans1OR 0.918

1 study
  1. HMGCR is linked with worse walking pace in humans (genetically proxied inhibition, Mendelian randomization using UK Biobank LDL-C data) (OR = 0.918, P = 6.06 × 10-9).

    Humansgenetically proxied inhibition, Mendelian randomization using UK Biobank LDL-C data

Upstream

1

TFCP2

upin human cells1

1 study
  1. TFCP2 activates HMGCR in combination with SREBP2.

    Cellsin combination with SREBP2

More on TFCP2

Associations

13

Prostate cancer

downin humans1downin silico1OR 0.718–0.833

2 studies
  1. HMGCR is linked with a lower risk of prostate cancer in humans (genetically proxied inhibition, drug-target Mendelian randomization) (OR 0.718 (95% CI 0.559-0.924)).

    Humansgenetically proxied inhibition, drug-target Mendelian randomization

  2. HMGCR lowers the risk of prostate cancer in silico (Mendelian randomization IVW (GWAS ID: ieu-b-85)) (OR 0.833, 95% CI 0.726-0.954).

    In silicoMendelian randomization IVW (GWAS ID: ieu-b-85)

More on Prostate cancer

Abdominal aortic aneurysm

upin humans1

1 study
  1. HMGCR raises the risk of abdominal aortic aneurysm in humans.

    Review

More on Abdominal aortic aneurysm

Cellular senescence

upin humans1

1 study
  1. HMGCR is associated with cellular senescence in knee synovium of OA patients and OA mice.

    Humansin knee synovium of OA patients and OA mice

More on Cellular senescence

Fasting blood glucose

upin humans1

1 study
  1. HMGCR is associated with fasting blood glucose in humans.

    Humans

More on Fasting blood glucose

Type 2 diabetes

upin humans1OR 3.59

1 study
  1. HMGCR is linked with a higher risk of type 2 diabetes in humans (male non-smokers and light smokers) (OR 3.59, 95% CI 1.37–9.39, p = 0.0094).

    Humansmale non-smokers and light smokersmales

More on Type 2 diabetes

Clear cell ovarian cancer

mixedin humans1

1 study
  1. HMGCR is associated with clear cell ovarian cancer in humans (gene expression instrument, Mendelian randomization).

    Humansgene expression instrument, Mendelian randomizationfemales

More on Clear cell ovarian cancer

Major depressive disorder

upin humans1OR 1.16

1 study
  1. HMGCR is linked with a higher risk of Major depressive disorder in humans (genetically proxied inhibition) (OR 1.16, 95% CI 1.07-1.25).

    Humansgenetically proxied inhibition

More on Major depressive disorder

Lanosterol

mixedin humans1

1 study
  1. HMGCR is associated with lanosterol in humans.

    Humansserum

More on Lanosterol

Dementia

downin humans1OR 0.24

1 study
  1. HMGCR is linked with a lower risk of dementia in humans (genetic proxy for non-HDL-C lowering, shown by one-sample Mendelian randomization) (OR 0.24 (0.18-0.31)).

    Humansgenetic proxy for non-HDL-C lowering, shown by one-sample Mendelian randomizationper 1 mmol/L (39 mg/dL) lower non-HDL-C

More on Dementia

Osteoporosis

downin humans1

1 study
  1. HMGCR is linked with a lower risk of osteoporosis in humans (genetically proxied lipid-lowering variants (Mendelian randomization); also PCSK9).

    Humansgenetically proxied lipid-lowering variants (Mendelian randomization); also PCSK9

More on Osteoporosis

All 13

Latest

Dec 2025: 0Jan 2026: 11Feb 2026: 9Mar 2026: 10Apr 2026: 6May 2026: 2Jun 2026: 2Jul 2026: 4Aug 2026: 2Sep 2026: 1Oct 2026: 11Nov 2026: 462 papers in 12 months

See all 177 papers on HMGCR